Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII.
Six hemophilia A patients with inhibitors were treated with a continuous infusion of recombinant activated factor VII (rFVIIa) for various bleeding episodes. Bleeding episodes (n = 101) were treated according to a 12 h regular dose protocol or a shortened (6 h) augmented dose protocol. Patient response to therapy was assessed by symptomatic improvement within predefined timeframes. Although patient number was limited, both protocols appeared similar with respect to the proportion of patients responding to therapy; however, the augmented dose protocol appeared to be superior to the regular dose protocol with shorter response time, shorter duration of therapy and possibly lower rFVIIa requirements. Further studies are needed to define the efficacy of rFVIIa augmented dose administered as continuous infusion in treating hemophilia patients with inhibitors during major bleeding episodes, trauma and surgery.
Kenet
G
G
National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel.
Lubetsky
A
A
Gitel
S
S
Luboshitz
J
J
Varon
D
D
Martinowitz
U
U
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D015942:Factor VIIa / Q000008:administration & dosage*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage*
D000906:Antibodies; D011994:Recombinant Proteins; D015942:Factor VIIa